PMID- 20014981
OWN - NLM
STAT- MEDLINE
DCOM- 20100520
LR  - 20220331
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 26
IP  - 3
DP  - 2010 Mar
TI  - Treatment retention with risperidone long-acting injection: 24-month results from 
      the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six 
      countries.
PG  - 501-9
LID - 10.1185/03007990903488670 [doi]
AB  - OBJECTIVE: To assess treatment retention on risperidone long-acting injection 
      (RLAI) and outcomes in schizophrenia patients for whom 24 months of follow-up 
      data in the electronic Schizophrenia Treatment Adherence Registry (e-STAR) were 
      available. RESEARCH DESIGN AND METHODS: e-STAR is an ongoing, international, 
      multicenter, prospective, observational registry assessing use of antipsychotics 
      in patients with schizophrenia or schizoaffective disorder in a normal clinical 
      practice setting. Parameters were assessed prior to and post-initiation of RLAI. 
      Data presented are from six European countries that enrolled patients in e-STAR 
      after they initiated treatment with RLAI. MAIN OUTCOME MEASURES: Clinical and 
      demographic information were collected at baseline and treatment-related data, 
      including RLAI discontinuation, psychiatric hospitalization and medication 
      utilization, were collected prospectively every 3 months. Data collection 
      continued for 24 months, even for patients who discontinued RLAI therapy. 
      Hospitalization and medication utilization were also collected retrospectively by 
      chart review for the 12-month period prior to RLAI initiation. RESULTS: A total 
      of 1659 patients (mean age, 39.2; 18.3% inpatients) completed the study. 
      Twenty-four months after initiating therapy (initial RLAI dose = 33.6 mg) 85% of 
      patients (n = 1410) remained on RLAI (completers) while 15% discontinued therapy. 
      The main reasons for discontinuation were insufficient response (28.5%), 
      patient/family choice (26.1%), adverse events (9.6%) and unacceptable 
      tolerability (6.0%). At baseline, compared to completers, discontinuers were 
      younger (37.4 vs. 39.6 years, p = 0.01), had schizophrenia for a shorter time 
      (10.2 vs. 11.9 years, p = 0.02), had lower Global Assessment of Functioning (GAF) 
      scores (43.5 vs. 48.0, p = 0.0001), higher utilization of benzodiazepines (56.5 
      vs. 43.3%) and more initiated therapy as inpatients (30 vs. 16%). With RLAI 
      therapy GAF scores improved significantly (p < 0.001) for both groups but the 
      24-month value for discontinuers was lower than that of completers (55.4 vs. 
      67.2). Compared to the pre-RLAI initiation period, at 12 months post-initiation 
      completers had greater reductions than discontinuers in the percent of patients 
      hospitalized (66.2% reduction vs. 29.2%) and in the length (68% reduction vs. 0%) 
      and number (80.0 vs. 14.3%) of hospital stays, differences that remained at 24 
      months. The most common adverse events while patients were taking RLAI were 
      nervous system disorders (6.8%), psychiatric disorders (5.6%), weight increase 
      (3.2%), reproductive system and breast disorders (2.5%) and gastrointestinal 
      disorders (2.1%). CONCLUSIONS: These observational data confirm that RLAI is an 
      effective treatment in schizophrenia and high levels of adherence to therapy 
      offers an opportunity for effective long-term disease management and significant 
      sustained decreases in hospitalization.
FAU - Peuskens, J
AU  - Peuskens J
AD  - Universitair Psychiatrisch Centrum, KU Leuven campus UC St. Jozef Kortenberg, 
      Belgium. jozef.peuskens@med.kuleuven.be
FAU - Olivares, J M
AU  - Olivares JM
FAU - Pecenak, J
AU  - Pecenak J
FAU - Tuma, I
AU  - Tuma I
FAU - Bij de Weg, H
AU  - Bij de Weg H
FAU - Eriksson, L
AU  - Eriksson L
FAU - Resseler, S
AU  - Resseler S
FAU - Akhras, K
AU  - Akhras K
FAU - Jacobs, A
AU  - Jacobs A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Antipsychotic Agents)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/*administration & dosage/adverse effects/economics
MH  - Female
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - *Medication Adherence
MH  - Prospective Studies
MH  - *Registries
MH  - Risperidone/*administration & dosage/adverse effects/economics
MH  - Schizophrenia/*drug therapy/economics
MH  - Time Factors
EDAT- 2009/12/18 06:00
MHDA- 2010/05/21 06:00
CRDT- 2009/12/18 06:00
PHST- 2009/12/18 06:00 [entrez]
PHST- 2009/12/18 06:00 [pubmed]
PHST- 2010/05/21 06:00 [medline]
AID - 10.1185/03007990903488670 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2010 Mar;26(3):501-9. doi: 10.1185/03007990903488670.